Abstract:Background Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that lacks hormone receptors and HER2 amplification, making it unresponsive to standard hormone or HER2-targeted therapies. Although immune checkpoint inhibitors (ICIs) have shown promise in tumors with high lymphocyte infiltration, their efficacy remains limited in tumors with minimal lymphocyte infiltration. To overcome this challenge, we developed a novel approach to reprogram tumor-associated macrophages (TAMs) from an immunosuppressive to an inflammatory phenotype within the tumor microenvironment (TME), aiming to enhance therapeutic outcomes in TNBC. Methods We designed a chimeric cytokine receptor (ChCR) that triggers STAT1 signaling upon stimulation with IL-10 or TGFβ, cytokines prevalent in the TME that typically drive immunosuppression. Human primary macrophages were transduced with a lentiviral vector expressing the ChCR, and changes in their phenotype, secretome, and transcriptome were analyzed following stimulation. The anti-tumoral activity of these reprogrammed macrophages was assessed using co-culture assays with 3D TNBC spheroids. Results ChCR expressing macrophages showed robust STAT1 activation in response to IL-10 or TGFβ stimulation, resulting in an inflammatory phenotype similar to IFNγ activation, as confirmed by phenotypic markers, and transcriptomic profiling. These ChCR-stimulated macrophages demonstrated significant anti-tumoral effects in 3D TNBC spheroids. Moreover, ChCR stimulation led to the upregulation of genes associated with good response to ICIs, among others CXCL9 and CXCL10, chemokines essential for lymphocyte recruitment. Secretion of CXCL10 was also confirmed by ELISA. Conclusion We successfully engineered a ChCR that reprograms TAMs within an IL-10- and TGFβ-rich environment, inducing an inflammatory phenotype and anti-tumoral activity. The expression of CXCL9 and CXCL10 further supports lymphocyte recruitment, potentially facilitating greater lymphocyte infiltration and disrupting the immunosuppressive TME. This approach offers a promising strategy to improve immunotherapy outcomes in TNBC patients, particularly those with low immune cell infiltration, thereby addressing a critical unmet clinical need.

Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression

Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression

Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses.

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis

In vivo macrophage engineering as novel therapeutic strategy against liver metastasis

Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases

Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment

Myeloid cell‐based delivery of IFN‐γ reprograms the leukemia microenvironment and induces anti‐tumoral immune responses

Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and anti-tumoral activity upon IL-10 or TGFβ stimulation

Induction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases

Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis

Efficacy of IFN-γ, sCD40L, and Poly(I:C) Treated Bone Marrow-Derived Macrophages in Murine Mammary Carcinoma

Immunotherapy of Melanoma Metastasis by Adoptive Transfer of M-CSF Or/and IFN-γ Gene Modified Macrophages Pulsed with Tumor Extracts

CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy

Dual Targeted Immunotherapy Via in Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells

Genetically Engineered Membrane-Based Nanoengagers for Immunotherapy of Pancreatic Cancer